Skip to main content

Table 1 Demographic and metabolic characteristics of study population by group

From: Cardiac structure and function are altered in type 2 diabetes and Non-alcoholic fatty liver disease and associate with glycemic control

Variable

Controls

NAFLD

Type 2 diabetes

P value

(n = 19)

(n = 19)

(n = 19)

Age (yr)

56 ± 14

54 ± 15

62 ± 8

0.127

Gender (men:women)

11:8

11:8

11:8

-

Height (cm)

169 ± 11

169 ± 9

168 ± 9

0.877

Weight (kg)

78 ± 11

83 ± 14

91 ± 14*

0.013

BMI (kg/m2)

28 ± 4

29 ± 3*

33 ± 5*

0.012

Body surface area (m2)

1.9 ± 0.2

1.9 ± 0.2

2.0 ± 0.2*

0.018

Visceral adipose tissue (cm2)

-

154 ± 47

191 ± 75

0.120

Systolic blood pressure (mmHg)

131 ± 11

146 ± 16*

145 ± 17*

0.003

Diastolic blood pressure (mmHg)

82 ± 8

90 ± 12

89 ± 12

0.096

VO2peak (ml min−1 kg−1)

-

24 ± 6

19 ± 5†

0.007

Fasting Glucose (mmol/L)

5.2 ± 0.5

5.0 ± 0.6

7.2 ± 1.4*†

0.000

HbA1c (mmol/mol)

-

38 ± 5

58 ± 10†

0.000

(%)

 

(5.6 ± 0.4)

(7.4 ± 0.9)

 

Intrahepatic lipid (%)

2.5 ± 0.9

9.4 ± 4.3*

7.9 ± 6.7*

0.000

ALT (U.L)

23 ± 12

51 ± 39*

30 ± 11

0.013

Total cholesterol (mmol/L)

5.3 ± 0.7

5.1 ± 1.2

4.7 ± 1.4

0.342

Triglycerides (mmol/L)

1.7 ± 0.9

1.5 ± 0.8

1.3 ± 1.1

0.328

Medications

   

-

Statins

0

4

10

 

Blood pressure

0

1

8

 

Metformin

0

0

12

 
  1. Data are means ± SD.
  2. *Significant difference disease vs. control (p < 0.05).
  3. †Significant difference Type 2 diabetes vs. NAFLD (p < 0.05).
  4. VO2peak, peak oxygen consumption; ALT, alanine aminotransferase.